Abstract
Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have